Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ardent Health, Inc. for possible securities fraud following significant financial disclosures that negatively impacted the company's stock price [1][3]. Financial Disclosures - On November 12, 2025, Ardent reported a $43 million reduction in revenue due to changes in accounting estimates regarding the collectability of accounts receivable [3]. - The company also disclosed a $54 million increase in its professional liability reserves related to claims in New Mexico [3]. - Following these disclosures, Ardent's stock price experienced a significant decline during pre-market trading on November 13, 2025 [3]. Legal Actions - Investors are encouraged to contact the Portnoy Law Firm to discuss their legal rights and potential claims for recovering losses [2]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo made false statements and concealed significant issues regarding its infant formula business acquired from Nestlé, including underinvestment in maintenance and operational improvements [3]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated estimates to address deficiencies in the infant formula business [3]. - The complaint highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [3]. - As a result of these issues, the positive statements made by Perrigo regarding its business and prospects were deemed materially misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take existing Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 5, 2025, and July 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that defendants made false statements and concealed material adverse facts regarding the company's medical cost trend assumptions [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical cost trends, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - The lawsuit suggests that Molina's near-term growth relied on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services, which misled investors about the company's business prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].

Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that inflated its financial metrics, impacting investors negatively between May 16, 2024, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [3]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements and concealed the fact that CarMax's growth was overstated, attributing earlier growth in the 2026 fiscal year to temporary benefits from customer speculation regarding tariffs [2]. - It is alleged that the statements made about CarMax's business, operations, and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [2]. Group 2: Next Steps for Investors - Investors who suffered losses in CarMax, Inc. during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Stride, Inc. for alleged securities fraud affecting investors between October 22, 2024, and October 28, 2025 [1][2]. Group 1: Allegations Against Stride, Inc. - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" [2]. - It is alleged that Stride cut staffing costs by assigning teachers' caseloads beyond statutory limits [2]. - The company is accused of ignoring compliance requirements, including background checks and licensure laws for employees, as well as federally mandated special education services [2]. - Whistleblowers who documented financial directives from Stride's leadership were reportedly suppressed, which included delaying hiring and denying services to maintain profit margins [2]. - The lawsuit also states that Stride has lost existing and potential enrollments due to these practices [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 12, 2026, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Primo Brands Corporation / Primo Water Corporation, alleging securities fraud related to the merger with BlueTriton Brands, which has reportedly faced significant operational issues [1][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud occurring between June 17, 2024, and November 6, 2025 [2]. - The complaint claims that the defendants made false statements regarding the merger integration, which was reportedly tracking poorly due to technology and service issues [3]. - Contrary to the defendants' assurances of a "flawless" execution, the company faced major supply disruptions that negatively impacted customers and financial results [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 12, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].